Cisplatin (cisdichlorodiammineplatinum 11) is used increasingly in the chemotherapy of malignant tumours, including carcinoma of the bronchus.We report here two cases of dilutional hyponatraemia secondary to the inappropriate secretion of antidiuretic hormone that developed in two patients with bronchial carcinoma receiving treatment with cisplatin. A 62 year old man developed malaise, weight loss, cough, and hypertrophic pulmonary osteoarthropathy and was found to have an undifferentiated squamous cell carcinoma of the bronchus, confirmed by biopsy of an endoscopically visible bronchial lesion. As the tumour was inoperable he began treatment with cycles of cisplatin 100 mg/m2 and etoposide 110 mg/i2 given intravenously at three weekly intervals. Before and during each infusion of cisplatin a period of prehydration and mannitol diuresis was instituted.' He became increasingly drowsy after receiving the cisplatin infusion and within 24 hours of the start of the infusion had two grand mal convulsions. Although the plasma sodium concentration was normal before treatment, hyponatraemia was now noted and the syndrome of inappropriate antidiuretic hormone secretion was diagnosed on the basis of the urine and plasma osmolalities in the presence of normal renal function (table) .
Cisplatin (cisdichlorodiammineplatinum 11) is used increasingly in the chemotherapy of malignant tumours, including carcinoma of the bronchus.We report here two cases of dilutional hyponatraemia secondary to the inappropriate secretion of antidiuretic hormone that developed in two patients with bronchial carcinoma receiving treatment with cisplatin.
Ca repof CASE 1
A 61 year old woman presented with a two day history of pleuritic chest pain and a productive cough. Material obtained by biopsy of an endoscopically visible bronchial tumour showed appearances of small cell undifferentiated carcinoma. Staging procedures suggested that this was confined to the thorax. Haematological and biochemical indices were normal. She commenced treatment with two cycles of intravenous vincristine 1*2 mg/m2, adriamycin 40 mg/i2, and cyclophosphamide 760 mg/i2, alternating with two cycles of intravenous cisplatin 100 mg/i2 and etoposide 110 mg/i2, at intervals of three weeks. Having completed the first two cycles uneventfully she was readmitted for her third cycle and before starting the cisplatin infusion underwent a period of prehydration with mannitol diuresis as described by Hayes et al 1977. ' The results of electrolyte and osmolality determinations before and after treatment are detailed in the table. Before treatment her blood pressure was 150/90 mm Hg and this did not alter appreciably during the period of fluid volume overload. The syndrome of inappropriate antidiuretic hormone secretion was diagnosed and fluid restriction was imposed, which resulted in the return of her serum electrolytes to normal within 10 days. Chemotherapy was subsequently continued without cisplatin and there were no further episodes of electrolyte disturbance during the course of her illness, although she failed to respond to chemotherapy and died six months after the onset of symptoms.
A 62 year old man developed malaise, weight loss, cough, and hypertrophic pulmonary osteoarthropathy and was found to have an undifferentiated squamous cell carcinoma of the bronchus, confirmed by biopsy of an endoscopically visible bronchial lesion. As the tumour was inoperable he began treatment with cycles of cisplatin 100 mg/m2 and etoposide 110 mg/i2 given intravenously at three weekly intervals. Before and during each infusion of cisplatin a period of prehydration and mannitol diuresis was instituted.' He became increasingly drowsy after receiving the cisplatin infusion and within 24 hours of the start of the infusion had two grand mal convulsions. Although the plasma sodium concentration was normal before treatment, hyponatraemia was now noted and the syndrome of inappropriate antidiuretic hormone secretion was diagnosed on the basis of the urine and plasma osmolalities in the presence of normal renal function (table) .
His blood pressure initially was 170/100 mm Hg and he remained mildly hypertensive throughout the period of fluid volume overload. He responded completely to fluid restriction and cisplatin was withdrawn from his treatment protocol. He died six weeks later from carcinomatosis without further evidence of serum electrolyte disturbance.
Discussion
Cisplatin has many side effects but there has been only one report of the syndrome of inappropriate antidiuretic hormone secretion after cisplatin infusion.2 The syndrome has also been documented after treatment with vincristine3 and cyclophosphamide,4 and raised plasma concentrations of antidiuretic hormone associated with emesis induced by chemotherapy5 has been reported. Neither of our patients, however, had more than mild nausea and vomiting after treatment and, although the first patient had received treatment with vincristine and cyclophosphamide, the normal plasma electrolytes before cisplatin infusion make it unlikely that the former drugs were responsible for the syndrome of inappropriate antidiuretic hormone secretion in this case. Fluid restriction of 500 mi/day was instituted from day 1 to day 8.
*Day 0 = day of cisplatin infusion.
Conversion: SI to traditional units-Sodium: 1 mmol = lmEq; urea: 1 mmol = 6 mg/100 ml; osmolality: 1 mmol = 1 mosmol. 
